BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 26907461)

  • 1. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
    Graff JN; Beer TM
    Oncology (Williston Park); 2015 Jun; 29(6):416-23. PubMed ID: 26091674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
    Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting bone metastases in prostate cancer: improving clinical outcome.
    Body JJ; Casimiro S; Costa L
    Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bone-targeted therapies for prostate cancer in 2017.
    Traboulsi SL; Saad F
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone and calcium metabolism associated with malignancy. Bone metastasis of prostate cancer:overview of clinical features and treatments.].
    Suzuki K; Miyazawa Y
    Clin Calcium; 2018; 28(11):1441-1449. PubMed ID: 30373999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
    Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
    Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
    Ryan CJ; Saylor PJ; Everly JJ; Sartor O
    Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    Bahl A
    Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.